A new immune evasion regulator in liver cancer — STK40. Its loss combined with anti-PD-1 led to complete tumor regression in preclinical models. Absea's anti-STK40 antibody supported validation throughout. Zhu et al., Cancer Cell 2026. ↓link in comment #Immunotherapy #CancerResearch #Oncology

June was a busy month. From conferences and scientific discussions to ongoing R&D, June kept us moving. We rounded it off with our annual team event on the Spandauer See. Thanks to everyone we met at ASMS, bio:cap Berlin, Drug Discovery Europe and the HRMS Symposium! #biotech #teammassspec

Ultra-sensitive protein detection isn't only about sensitivity. It's about controlling background. A recent PRIPA study reached 0.024 pg/mL detection of p-tau181 and used Absea GFAP and NfL reagents in its multiplex assay development. ↓ #Neurodegeneration #Biomarkers

Protein quantification often relies on one reference peptide, even though different peptides from the same protein yield different quantities. This doesn't necessarily mean something went wrong — part of your peptide population may carry a PTM or mutation. Which peptide are you trusting, and why?👇

A tumor that stops showing its ID can evade the immune system. MHC-I downregulation reduces antigen presentation and helps tumors escape CD8+ T cells. The challenge is seeing where it happens. #IHC preserves tissue architecture, which is why we've invested in HLA and B2M antibodies for FFPE tissue.

Longevity is not always about reducing oxidative stress. A new MDPI study suggests that paederoside (PSG) extends lifespan in C. elegans by promoting DAF-2/IGF1R degradation and activating DAF-16/FOXO and SKN-1/NRF2 signaling. The study used AKT3 and pAKT antibodies from Absea. #Aging #Longevity

What happens to an #antibody after it leaves our lab? For the ones we contribute to @proteinatlas.bsky.social, the results are public. Every reagent goes through independent evaluation, with validation data openly available to the research community. #Proteomics

The Human Protein Atlas welcomes GeneTex’s recent announcement formalizing a collaborative relationship with the Human Protein Atlas. Collaborations with Atlas Antibodies, NCI-CPTC, Thermo Fisher Scientific, and Absea Biotech are also acknowledged. www.proteinatlas.org/news/2026-05...

Better biomarkers are not about stronger signals but about the right signals. BD pTau217 selects brain-derived tau before measuring T217 phosphorylation—reducing the intermediate “gray zone” to 7%. An example of why antibody pair design matters and the idea behind our P2P2P workflow. #Alzheimers

Our SVP Philip Lössl will be attending Drug Discovery Europe 2026 in Berlin next week. If you'd like to discuss proteomics, endogenous protein capture, interactomics, or assay development, feel free to get in touch. #DrugDiscoveryEurope #Proteomics

MAU2 now has stronger CdLS support in a larger cohort. This new @natcomms.nature.com study reports 18 individuals, two mechanisms, and MAU2-specific methylation signatures. The Western blot work used our NIPBL antibody KT54. DOI: 👇 #Genetics

A day into bio:cap Europe in Berlin. Philip Lössl and Phoebe Wei are spending the week meeting partners and and taking part in discussions across the life sciences community. Still a little time left before the conference wraps up. #biocapeurope #biocap26 #proteomics

May. P2P2P (Pair → Pair → Product) introduced. Most of the month spent testing, refining, and moving projects forward. One evening, the team stepped outside the lab for a BBQ — might have started a new tradition in the process. #Biotech #LifeSciences #Berlin

#ASMS2026 has come to an end. It was a great few days in San Diego with discussions around crosslinking-MS, interactomics, quantitative proteomics, and IP-MS workflows, and interest around Clement Potel’s poster. Thank you to everyone who stopped by Booth #1022 and connected with the team!

We'll be at bio:cap in Berlin, June 9–11. Philip Lössl and Phoebe Wei attending — quantitative proteomics, interactomics, assay development on the agenda. The best conversations usually happen between sessions. Come find us. #biocapeurope #biocap26 #proteomics

Last day at #ASMS 2026. It’s been a great week of discussions around crosslinking-MS, interactomics, quantitative proteomics, and IP-MS workflows in San Diego. The team is still at Booth #1022 today if you’d like to stop by one last time before the conference wraps up. #teammassspec #proteomics

Crosslinking-MS, interactomics, quantitative proteomics… and apparently Abby, our mascot. Some traditions seem to follow us to every conference, and ASMS 2026 has been no exception. Stop by Booth #1022 this week and you might leave with a smaller one too. #ASMS2026 #teammassspec

Today at #ASMS2026. Clément Potel will present our latest work on high-throughput crosslinking-MS and large-scale interactome analysis from intact human cells. Poster TP079 10:30 AM – 2:30 PM #Proteomics #teammassspec

#ASMS2026 is underway. Tao Chen, Philip Lössl, and Clément Potel are in San Diego this week discussing interactomics, quantitative proteomics, and crosslinking-MS workflows. Come say hello at Booth #1022. Poster TP079 on Tuesday. #teammassspec #proteomics

How far can human interactome analysis be pushed in 24 hours? Clément Potel will share our latest work at #ASMS2026 on high-throughput crosslinking-MS workflows and large-scale interactome analysis from intact human cells. Poster TP079 Tuesday | 10:30 AM – 2:30 PM Booth #1022 See you soon!

LC–MS variability is less often the main limitation in proteomics, but inter-lab reproducibility still breaks more than expected. Peptide standards miss upstream variability. ¹⁵N protein standards at Absea follow the full workflow. Where do you see most variability? #teammassspec #proteomics

We’ll be at #ASMS2026 in San Diego (May 31–June 4). Clement Potel, Philip Lössl, and Tao Chen will be there at booth #1022. Happy to talk proteome-scale protein resources, N-15 workflows, IP-MS reagents, P2P2P antibody development, and related workflows. #teammassspec #biotech

Screening #antibodypairs in both recombinant #protein and cell lysate early changes what moves forward. Pairs that only work in ideal conditions drop out sooner. Especially when you're seeing unstable signals or low separation in plasma. That’s how we structure it with P2P2P.

Why does an antibody pair work in screening— then fail in plasma? Three reasons. 👇️ 1/5

#Antibodypairs look strong in screening. Then real samples behave differently. Usually not an antibody issue. It’s the screening conditions. If you're dealing with unstable signals or high background, this is usually where it starts. That’s the gap we work on with P2P2P. #Biotech

#Spatialbiology is shifting—from mapping cells to what they’re doing locally. In #immunology, that means cytokines: low-abundance, highly local, hard to measure. A real bottleneck. We built a pool of 128 IHC-validated antibodies to make cytokine detection in tissue less of a guessing game.

April. Analytica, German Biotech Days, AACR — three conferences, lots of conversations and perspectives. Back in the lab, MS running steadily and a new HPLC for peptide fractionation. A steady month overall, with work moving forward. Team dinner to wrap it up. #Biotech #LifeSciences #Proteomics

Same protein. Same sample. Different peptides can give different quantitative results. QC studies report ~38–56% differences between signature peptides under peptide-level calibration. Do you see this in your workflows?👇

Going to #ALDA in Boston this week. Lots of interesting conversations happening around #proteomics right now. Less about instrument and more about access, scale, and data. Our CEO and SVP, Tao Chen and Philip Lossl, will be there. If you’re attending, feel free to reach out.

We're seeing teams shift how they approach PROTACs now. #E3ligase selection used to be downstream. But projects exploring tissue selectivity or resistant pathways hit reality: VHL isn't always enough. KEAP1 works differently. But does it work in your cells? That's the question now. 👇 #biotech

Day 1 at German Biotech Days in Leipzig. Philip Lössl (SVP) here connecting with researchers and teams across biotech and life sciences. If you're attending and want to chat, feel free to say hello! #DBT2026 #Biotech

Attending AACR in San Diego, April 17–22. Tao Chen, our CEO, will be there meeting researchers and partners to discuss current challenges in cancer research. If you’re attending, we’d be glad to connect. #Biotech #AACR26

Heading to German Biotech Days in Leipzig (April 21–22). Our SVP Philip Lössl will be there connecting with the #proteomics community. If you’re in the space, happy to chat. 🧬 #biotech #DBT2026

Everyone’s generating more data. Making sense of it is another story. At analytica (Munich) and NextGen Omics (Boston), we saw the same challenge across spatial and multi-omics. At Absea, we’re focusing on #spatialbiology and generating clinical #proteomics data. #biotech

We’ve upgraded our autoimmune antigen portfolio with full epitope coverage & native-like folding: • Jo-1: full-length, N-terminal epitopes • SNRPB: expanded 80 → 240 aa • Scl-70: optimized eukaryotic expression • ANCA antigens: mammalian expression for proper activity

Busy month for the lab: MS arrived. New freezer and nitrogen generator. Back on the conference circuit. Cubeer round two. Team dinner last week at a French restaurant, part of our rotating cuisine habit with our multicultural team. #Biotech #LifeSciences #teammassspec #proteomics

Your LC-MS assay validates beautifully. R² > 0.99. Then you test real plasma QCs with known protein amounts. Using heavy peptide standards: → −23% to −62% systematic bias So what’s going on?

Final day at #analytica in Munich 👋 It’s been a great few days meeting people across biotech and lab tech. Our SVP Philip Lössl is there for Absea today. If you’re around, feel free to say hi or just message us here! #biotech #labtech #munich

Heading to nextgen omics in boston (march 31 – april 1) to connect with the spatial biology & multi-omics community. Philip Lossl (SVP) representing Absea. if you'll be there and want to chat about what we're building, DM us, we have slots for 1:1s 🧬 #NextGenOmics

Last week we teased this box. As some of you guessed, it's a Bruker timsUltra AIP. Enhanced sensitivity and throughput, expanding our analytical capabilities. Supporting faster progress on our Architectomics pipelines. Excited to get it running 🔬 #Biotech #teammassspec

heading to analytica in munich (march 24–27) to connect with the lab tech & biotech community! Philip Lössl (SVP) will be there representing Absea. if you're attending and want to chat about what we're building, we’ve got a few 1:1 slots 🔬 #analytica

Something big just arrived in the lab again. Any guesses what’s in this box? Full reveal next week. #LabLife #Biotech #TeamScience

Lab upgrade🔬 New freezer. New nitrogen gas generator. Heavy lifts, careful moves, and a lot of teamwork to make our lab keep growing. #LabLife #Biotech #TeamScience

📢 Publication Spotlight: We've studied cell signaling like someone searching for lost keys under a streetlight — not because that's where they fell, but because that's where the light is. New paper in @natcomms.nature.com puts a number on how much we've been missing. 1/3

We organized a casual get-together for the biotech teams in our building — Meet Your New Neighbor. Simple idea. The kind of thing you assume will happen eventually, until you just start it. Food, drinks, good conversations. Thanks to everyone who joined, already planning the next one!

CDH6, CDH17, CDH3 — from EMT textbooks to clinical-stage ADC programs in just a few years. Translation is accelerating. But the foundational question remains: How is your target expressed in real patient tissue? IHC still provides the answer. We develop validated antibodies to support that work.👇

Multi-site #proteomics studies require cross-lab consistency. Fold-change comparisons can vary between sites. ¹⁵N-labeled full-length protein standards integrate before extraction and move through digestion and LC-MS, improving cross-site reproducibility and validation robustness. #Biomarkers

We have a new biosafety cabinet. Instead of calling movers, we moved it ourselves — across campus to our new lab at Campus Berlin-Buch GmbH. Five hours. Careful lifting. A lot of hands. And just like that, it’s in the lab. #Biotech #LabLife

Custom #antibodies often fail in assays where they weren’t tested. We provide hybridoma supernatants to test in your workflow before clone selection. Sequenced antibodies remove hybridoma dependence. 4,700+ projects. 18–24 weeks. absea.bio

Paper Highlight: Tumor-reactive T cells aren't only tumor-resident—peripheral blood supplies them during checkpoint therapy. Li et al. (Cell Stem Cell) GLI model captures this ex vivo. Our anti-LAMP3 KC-1563 identified mature DCs coordinating infiltration. 🔗 www.cell.com/cell-stem-ce...